Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

Secerna Website Images 2023 (49)

European, Industry news 17/06/2024

Romania to Join the Unitary Patent System

Secerna Website Images 2023 (49) (1)

Events, News 12/06/2024

Secerna to attend Northern Powerhouse Investment Fund event in York

B012621

Events, News 11/06/2024

Secerna to attend BioFocus Conference 2024 in Newcastle

UK & USA

Industry news, News 10/06/2024

UK and US Intellectual Property Offices Join Forces on Standard Essential Patents

JP3 2544

Industry news, News, Team news 05/06/2024

Secerna Earns Fourth Consecutive IAM 1000 Recognition

EPO 2021

European, News, UPC 04/06/2024

Noteworthy Start for Europe's Unified Patent System One Year On

Building A Robust Biotech Patent Portfolio

Industry news, News 30/05/2024

Building a Robust Patent Portfolio to Navigate the Biotech Landscape

World Intellectual Property Organization Geneva

Industry news, News 24/05/2024

Landmark U.N. Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge

Laos

European, News 22/05/2024

New Route to Patent Protection in Laos through validation of European Patents

6 7 8 9 10 11 12 13 14 15 16